替诺脯 | 138511-81-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 替诺脯
• 中文别名: 艾考度林
• 英文名称: Icoduline
• 英文别名: 5-methyl-2-(1,3-thiazol-2-ylamino)phenol
• CAS: 138511-81-6
• 化学式: C₁₀H₁₀N₂OS
• 分子量: 206.27
• InChiKey: UTHOTQDPKFKRKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  73.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Substituted urea and isothiourea derivatives as no synthase inhibitors
  申请人：——

  公开号：US20010034342A1

  公开（公告）日：2001-10-25

  The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerebral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.

  本发明涉及使用N-取代脲衍生物制备药物，用于治疗需要抑制NO合酶酶的情况，特别是脑缺血，并公开了相应的制剂。同时还描述了新型N-取代脲衍生物及其制备方法。
• Novel compositions and methods for treating hyperproliferative diseases
  申请人：Chen, Chien-Hung

  公开号：EP2123267A1

  公开（公告）日：2009-11-25

  The invention relates to a composition that includes a first agent selected including an agent that possesses anti-inflammatory activity or acetaminophen, phenacetin, tramadol and the like; a second agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5-monophosphate-activated Protein kinase (AMPK) activator; a third agent that possesses or maintains serotonin activity.

  本发明涉及一种组合物，其中包括第一种药剂，选自具有抗炎活性的药剂或对乙酰氨基酚、苯乙哌啶、曲马多等；第二种药剂，选自氧化磷酸化抑制剂、离子贮存剂和腺苷-5-单磷酸激活蛋白激酶（AMPK）激活剂；第三种药剂，具有或保持血清素活性。
• Novel composition for treating metabolic syndrome
  申请人：IPINTL, LLC

  公开号：EP2494967A1

  公开（公告）日：2012-09-05

  The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5'-monophosphate-activated Protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.

  本发明涉及一种组合物，其中包括选自氧化磷酸化抑制剂、离子贮存剂和腺苷-5'-单磷酸激活的蛋白激酶（AMPK）激活剂组成的组的第一种药剂；具有抗炎活性的第二种药剂；以及具有血清素活性的第三种药剂。
• Methods and reagents for the treatment of metabolic disorders
  申请人：Lee S. Margaret

  公开号：US20060069161A1

  公开（公告）日：2006-03-30

  The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.

  本发明的特点是用于治疗糖尿病和肥胖症等代谢性疾病的组合物、方法和试剂盒。